ArticleInfection and immunity2008
CD46 Contributes to the severity of group A streptococcal infection.
Article in Infection and immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Blocking Extracellular Cyclophilin A-Mediated Adhesion Protects Against Bacterial Infection.MedComm · 2026Article
- Mechanisms of host adaptation by bacterial pathogens.FEMS microbiology reviews · 2024Review
- The Role of Gram-Positive Surface Proteins in Bacterial Niche- and Host-Specialization.Frontiers in microbiology · 2020Review
- Inflammatory Joint Disease Is a Risk Factor for Streptococcal Sepsis and Septic Arthritis in Mice.Frontiers in immunology · 2020Article
- Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic.Molecular therapy. Methods & clinical development · 2016Article
- Complement regulator CD46: genetic variants and disease associations.Human genomics · 2015Review
- Genetic Dissection of the Host Tropism of Human-Tropic Pathogens.Annual review of genetics · 2015Review
- Molecular basis of host specificity in human pathogenic bacteria.Emerging microbes & infections · 2014Review
- CD46 processing: a means of expression.Immunobiology · 2012Review
- Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Lactobacilli reduce cell cytotoxicity caused by Streptococcus pyogenes by producing lactic acid that degrades the toxic component lipoteichoic acid.Antimicrobial agents and chemotherapy · 2011Article
- [Necrotizing fasciitis. 2011 update].Der Unfallchirurg · 2011Article
- CD46 plasticity and its inflammatory bias in multiple sclerosis.Archivum immunologiae et therapiae experimentalis · 2011Review
- Olfactory nerve--a novel invasion route of Neisseria meningitidis to reach the meninges.PloS one · 2010Article
- Presenilin/gamma-secretase cleaves CD46 in response to Neisseria infection.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- CD46 transgenic mouse model of necrotizing fasciitis caused by Streptococcus pyogenes infection.Infection and immunity · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptococcus pyogenes (group A Streptococcus) is a human pathogen that causes a wide variety of diseases ranging from uncomplicated superficial infections to severe infections such as streptococcal toxic shock syndrome and necrotizing fasciitis. These bacteria interact with several host cell receptors, one of which is the cell surface complement regulator CD46. In this study, we demonstrate that infection of epithelial cells with S. pyogenes leads to the shedding of CD46 at the same time as the bacteria induce apoptosis and cell death. Soluble CD46 attached to the streptococcal surface, suggesting that bacteria might bind available extracellular CD46 as a strategy to survive and avoid host defenses. The protective role of human CD46 was demonstrated in ex vivo whole-blood assays showing that the growth of S. pyogenes was enhanced in blood from mice expressing human CD46. Finally, in vivo experimental infection showed that bacteremia levels, arthritis frequency, and mortality were higher in CD46 transgenic mice than in nontransgenic mice. Taken together, these results argue that bacterial exploitation of human CD46 enhances bacterial survival and represents a novel pathogenic mechanism that contributes to the severity of group A streptococcal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.